Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model One out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading down 30 points (-0.2%) at 15,089 as of Monday, May 13, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,245 issues advancing vs. 1,704 declining with 112 unchanged. The Health Services industry currently sits up 0.3% versus the S&P 500, which is unchanged. On the negative front, top decliners within the industry include Agilent Technologies ( A), down 1.97, Fresenius Medical Care AG & Co. KGaA ( FMS), down 1.43 and Grifols ( GRFS), down 0.95. Top gainers within the industry include St Jude Medical ( STJ), up 2.3%, Stryker Corporation ( SYK), up 0.8% and Zimmer Holdings ( ZMH), up 0.8%. TheStreet Ratings group would like to highlight 5 stocks pushing the industry lower today: 5. DaVita HealthCare Partners ( DVA) is one of the companies pushing the Health Services industry lower today. As of noon trading, DaVita HealthCare Partners is down $0.98 (-0.8%) to $130.21 on average volume Thus far, 576,495 shares of DaVita HealthCare Partners exchanged hands as compared to its average daily volume of 871,900 shares. The stock has ranged in price between $128.73-$130.87 after having opened the day at $129.91 as compared to the previous trading day's close of $131.19. DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure, or end stage renal disease (ESRD) in the United States. DaVita HealthCare Partners has a market cap of $13.6 billion and is part of the health care sector. The company has a P/E ratio of 30.8, above the S&P 500 P/E ratio of 17.7. Shares are up 16.3% year to date as of the close of trading on Friday. TheStreet Ratings rates DaVita HealthCare Partners as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full DaVita HealthCare Partners Ratings Report now. Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.